Milestone Pharmaceuticals (MIST) Total Non-Current Liabilities (2020 - 2026)
Milestone Pharmaceuticals (MIST) posted Total Non-Current Liabilities of $102.0 million for Q1 2026, up 42.29% on a QoQ basis from $71.7 million in Q4 2025, and up 583.34% year-over-year from $14.9 million in Q1 2025.
Milestone Pharmaceuticals (MIST) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Milestone Pharmaceuticals' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $102.0 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 583.34% year-over-year to $102.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.0 million (up 583.34% YoY) and the FY2025 annual result came in at $71.7 million, up 673.06% from the prior year.
- Total Non-Current Liabilities was $102.0 million for Q1 2026 at Milestone Pharmaceuticals, up from $71.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $102.0 million in Q1 2026 and bottomed at -$48.3 million in Q2 2022.
- A 5-year average of $6.2 million and a median of $8.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 65.42% — and 2025, when it soared 673.06%.
- Milestone Pharmaceuticals' Total Non-Current Liabilities stood at -$26.2 million in 2022, then jumped by 138.13% to $10.0 million in 2023, then fell by 7.2% to $9.3 million in 2024, then surged by 673.06% to $71.7 million in 2025, then jumped by 42.29% to $102.0 million in 2026.
- Business Quant data shows MIST's Total Non-Current Liabilities at $102.0 million in Q1 2026, $71.7 million in Q4 2025, and $11.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Milestone Pharmaceuticals | 156.34 Mn | -27.87 Mn | - | 102.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.04 Mn |
| Dec 31, 2025 | 71.71 Mn |
| Sep 30, 2025 | 11.60 Mn |
| Jun 30, 2025 | 12.09 Mn |
| Mar 31, 2025 | 14.93 Mn |
| Dec 31, 2024 | 9.28 Mn |
| Sep 30, 2024 | 5.62 Mn |
| Jun 30, 2024 | 4.18 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | 10.15 Mn |
| Jun 30, 2023 | 8.15 Mn |
| Mar 31, 2023 | 8.69 Mn |
| Dec 31, 2022 | -26.22 Mn |
| Sep 30, 2022 | -44.33 Mn |
| Jun 30, 2022 | -48.30 Mn |
| Mar 31, 2022 | -47.90 Mn |
| Dec 31, 2021 | -45.69 Mn |
| Sep 30, 2021 | -46.57 Mn |
| Jun 30, 2021 | -47.03 Mn |